['hepatitis c viral infection', 'chronic hepatitis c', 'hepatitis c (hcv)', 'hepatitis c genotype 4']
['faldaprevir', 'td-6450', 'ribavirin']

        Inclusion Criteria:

          -  Chronic genotype 4 hepatitis C infection and HCV RNA ≥ 10^4 IU/mL at screening

          -  Hepatitis C virus treatment naive, defined as defined as having never received a
             direct acting anti-viral (DAA), and as having received ≤ 8 weeks of interferon ≥ 6
             months prior to screening

          -  Absence of cirrhosis as defined by one of the following:

               -  A liver biopsy performed within 24 calendar months of Day 1 showing absence of
                  cirrhosis

               -  Transient elastography (FibroScan®) performed within 12 calendar months of Day 1
                  with a result of ≤ 12.5 kPa

               -  A FibroSure® score ≤ 0.48 and AST:platelet ratio (APRI) ≤ 1 performed during
                  screening

        Exclusion Criteria:

          -  Infection with hepatitis B virus (HBV) or human immunodeficiency virus, HIV-1 or HIV-2
      